Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The immune-modulating drug was approved to treat the rare cancer in HIV-positive and HIV-negative people.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
The Office of HIV and AIDS Malignancy at the National Cancer Institute coordinates cancer and HIV research.
Keytruda and Imfinzi showed response rates and safety profiles similar to those seen in HIV-negative people.
Treatment with checkpoint inhibitors appears safe and effective for HIV-positive people.
Researchers looked both at the first and second time people with HIV have been diagnosed with cancer.
Six out of nine patients experienced cancer remission with Opdivo or Keytruda.
Its decline after the advent of antiretroviral therapy did not extend to Black men in the South.
Declining rates are expected for Kaposi sarcoma, non–Hodgkin lymphoma, cervical and lung cancer and Hodgkin lymphoma, among others.
However, older people with HIV have a lower rate of a few other cancers compared with the general population.
National Comprehensive Cancer Network releases new Guidelines for best practices for treating patients with kaposi sarcoma
Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials.
With the HIV population aging, it is increasingly at risk of such age-related cancers.
However, compared with the general population, HIV-positive individuals remain at higher risk for a slew of malignancies.
Treating HIV early, before CD4s drop significantly, lowers the risk of infection-related cancers.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.